HomeNewsLumos acquires license for LUM-201 drug that promotes secretion of development hormone
Posted in News on 25th September 2018

Lumos Pharma, Inc., a scientific stage biopharmaceutical firm targeted on growth and commercialization of therapeutics for uncommon and uncared for ailments, right this moment introduced that it has acquired the license for LUM-201, an investigational orally administered small molecule that promotes secretion of development hormone from the pituitary gland, from Ammonett Pharma LLC. Lumos plans to provoke a Section IIb trial in 2019 in sufferers with Pediatric Development Hormone Deficiency (PGHD) to match a number of doses of LUM-201 to every day injections of recombinant human development hormone, which is the present normal of care. Rick Hawkins, CEO of Lumos Pharma, commented, “The Lumos traders and the complete Lumos staff are extraordinarily excited for the chance to quickly advance this oral candidate for PGHD sufferers. Many sufferers will probably admire a substitute for injections.” Michael Thorner, MB, BS, DSc, a number one endocrinologist primarily based on the College of Virginia and adviser to Lumos who has lengthy been concerned with this system whereas an govt at Ammonett Pharma, commented, “Lumos is the right firm to advance this remedy to approval. It has glorious uncommon illness drug growth experience and sources. I stay up for working with the staff on the product’s growth and commercialization.”



Related Post for New antibody can scale back swelling assaults in sufferers with hereditary angioedema

Botulinum toxin injections present promise to suppress postoperative atrial fibrillation
FDA: Critical Aspect Impact of AML Drug Not Being Acknowledged
New ointment for treating brown recluse spider bites is examined on people
FDA: MS Drug Linked to Circumstances of Stroke, Blood Vessel Wall Tears
New antibody can scale back swelling assaults in sufferers with hereditary angioedema